What are the treatment attributes preferred by UK patients with transthyretin amyloid cardiomyopathy?

11 May 2026 (16:00 - 17:30)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Louis Baig

Pfizer UK, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail

Impact of an educational intervention on pharmacological management of HFrEF in Italy: results from the multicenter OpTIMa-HF registry

Doctor M. Di Santo (Naples, IT)

Abstract Slides

Presentation thumbnail

Renal function and therapeutic inertia: a gap between eligibility and prescription of guideline-directed medical therapy in hospitalized reduced and mildly reduced ejection fraction patients

Doctor M. Silva (Amadora, PT)

Abstract Slides

Presentation thumbnail

Natriuretic response as a marker of decongestion in hospitalized patients with heart failure

Doctor S. Singh (Hartford, US)

Abstract Slides

Presentation thumbnail

No phenotype-based differences in discharge GDMT across the LVEF spectrum in acute heart failure: data from multicenter registry

Doctor M. Balabayeva (Aktobe, KZ)

Abstract Slides

Presentation thumbnail

Early initiation of SGLT2-inhibitors and changes in physical function in elderly patients hospitalized for heart failure

Doctor Y. Nishihata (Tokyo, JP)

Abstract Slides

Access the full session

Session thumbnail

ePosters in acute heart failure - pharmacotherapy (2)

The Event

Event poster

Heart Failure 2026

11 May 2026 16:00 CET

You may be interested in

Congress Session

Acute heart failure therapies: from clinical trials to clinical practice

Congress Session

Devices in acute heart failure

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources